BMA
BMY icon

Brooks Moore & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Brooks Moore & Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$445K Hold
7,329
– – 0.22% 75
2025
Q4 		$395K Buy
7,329
+185
+3% +$8.9K 0.19% 81
2025
Q3 		$322K Hold
7,144
– – 0.16% 90
2025
Q2 		$309K Hold
7,144
– – 0.17% 92
2025
Q1 		$436K Hold
7,144
– – 0.25% 76
2024
Q4 		$404K Hold
7,144
– – 0.24% 73
2024
Q3 		$370K Sell
7,144
-15
-0.2% -$704 0.22% 72
2024
Q2 		$297K Hold
7,159
– – 0.19% 75
2024
Q1 		$388K Hold
7,159
– – 0.25% 69
2023
Q4 		$367K Hold
7,159
– – 0.25% 67
2023
Q3 		$416K Sell
7,159
-7,615
-52% -$467K 0.31% 62
2023
Q2 		$945K Sell
14,774
-470
-3% -$31.5K 0.67% 47
2023
Q1 		$1.06M Buy
15,244
+845
+6% +$59.6K 0.76% 41
2022
Q4 		$1.04M Buy
14,399
+425
+3% +$32K 0.76% 41
2022
Q3 		$993K Hold
13,974
– – 0.8% 41
2022
Q2 		$1.08M Hold
13,974
– – 0.78% 42
2022
Q1 		$1.02M Sell
13,974
-925
-6% -$62.1K 0.63% 48
2021
Q4 		$929K Sell
14,899
-14,980
-50% -$879K 0.54% 47
2021
Q3 		$1.77M Buy
29,879
+168
+0.6% +$11.1K 1.16% 36
2021
Q2 		$1.99M Buy
29,711
+4,600
+18% +$300K 1.27% 34
2021
Q1 		$1.58M Buy
25,111
+836
+3% +$52K 1.07% 38
2020
Q4 		$1.51M Buy
24,275
+700
+3% +$43K 1.17% 36
2020
Q3 		$1.42M Buy
23,575
+1,890
+9% +$114K 1.23% 34
2020
Q2 		$1.27M Buy
21,685
+4,222
+24% +$253K 1.19% 31
2020
Q1 		$973K Buy
17,463
+1,770
+11% +$108K 1.03% 37
2019
Q4 		$1.01M Sell
15,693
-2,545
-14% -$146K 0.8% 43
2019
Q3 		$925K Buy
18,238
+3,225
+21% +$152K 0.78% 47
2019
Q2 		$681K Buy
15,013
+740
+5% +$34.5K 0.58% 61
2019
Q1 		$681K Hold
14,273
– – 0.62% 54
2018
Q4 		$742K Buy
+14,273
New +$767K 0.75% 51

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brooks Moore & Associates's BMY Position: Q1 2026 in Review

Brooks Moore & Associates held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 7,329 shares worth $445K. The position accounts for 0.22% of the portfolio, ranked #75.

Brooks Moore & Associates first reported a position in BMY in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.99M in Q2 2021. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Brooks Moore & Associates held 7,329 shares of Bristol-Myers Squibb worth $445K as of Q1 2026.
  • Brooks Moore & Associates left its Bristol-Myers Squibb share count unchanged in Q1 2026.
  • Bristol-Myers Squibb made up 0.22% of Brooks Moore & Associates's portfolio in Q1 2026, its #75 holding.
  • Brooks Moore & Associates first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 30 quarters since.
  • Brooks Moore & Associates's Bristol-Myers Squibb position peaked at $1.99M in Q2 2021.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Brooks Moore & Associates's 13F filing for Q1 2026, filed 15 May 2026.